title: Healing the damaged mesangium in nodular glomerulosclerosis using mesenchymal stem cells (MSCs): Expectations and challenges.
abstract: It has been shown experimentally that mesenchymal stem cells (MSCs) can be delivered to the mesangium in some conditions such as amyloidosis to clear debris and foreign material, and eventually transform into functional mesangial cells (MCs) and change the altered mesangial areas into normal collagen IV-rich matrix. A more challenging situation is when the matrix is rich in abnormal extracellular matrix proteins, especially those difficult to destroy such as tenascin, and, as a result, assumes a nodular appearance - what is known in pathology jargon as nodular glomerulosclerosis. MSCs find it difficult to dispose of the altered mesangial constituents, an initial step required for mesangial repair to occur successfully. The ability of MSCs to repair damaged mesangium represents a novel therapeutic intervention to reverse mesangial injury and is potentially a powerful and unique approach to prevent progression ending in end-stage renal disease (ESRD). This review will highlight progress that has been made in glomerular, and more specifically mesangial, repair, and will address future expectations and challenges to be confronted as the use of MSCs continues to be explored as a potential application for clinical practice.
authors.affiliation: a Department of Pathology and Translational Pathobiology , Louisiana State University Health Sciences Center , Shreveport , LA , USA.|b Department of Cellular Biology and Anatomy , Louisiana State University Health Sciences Center , Shreveport , LA , USA.
authors.forename: Guillermo A
authors.initials: GA
authors.lastname: Herrera
authors.affiliation: a Department of Pathology and Translational Pathobiology , Louisiana State University Health Sciences Center , Shreveport , LA , USA.
authors.forename: Chun
authors.initials: C
authors.lastname: Zeng
authors.affiliation: a Department of Pathology and Translational Pathobiology , Louisiana State University Health Sciences Center , Shreveport , LA , USA.|b Department of Cellular Biology and Anatomy , Louisiana State University Health Sciences Center , Shreveport , LA , USA.|c Department of Medicine, Feist-Weiller Cancer Center , Louisiana State University Health Sciences Center , Shreveport , LA , USA.
authors.forename: Elba A
authors.initials: EA
authors.lastname: Turbat-Herrera
authors.affiliation: a Department of Pathology and Translational Pathobiology , Louisiana State University Health Sciences Center , Shreveport , LA , USA.
authors.forename: Jiamin
authors.initials: J
authors.lastname: Teng
mesh_terms: D000818:Animals; D001706:Biopsy; D003928:Diabetic Nephropathies / Q000276:immunology / Q000473:pathology / Q000503:physiopathology / Q000601:surgery*; D004195:Disease Models, Animal; D005109:Extracellular Matrix / Q000473:pathology; D005921:Glomerulonephritis / Q000276:immunology / Q000473:pathology / Q000503:physiopathology / Q000601:surgery*; D006801:Humans; D007147:Immunoglobulin Light Chains / Q000276:immunology; D007678:Kidney Glomerulus / Q000276:immunology / Q000473:pathology / Q000503:physiopathology / Q000601:surgery*; D045164:Mesenchymal Stem Cell Transplantation; D016896:Treatment Outcome; D014945:Wound Healing
chemical_list: D007147:Immunoglobulin Light Chains
keywords: Animal model; curcumin; growth factors; light chain deposition disease; light chains; mesangium; mesenchymal stem cells; regeneration; repair; retinoic acid